Peptide Therapy Research for Sports Medicine & Injuries

Athletes and active patients are increasingly turning to peptide therapies in hopes of recovering faster from injuries and enhancing physical performance — but how much of that enthusiasm is backed by rigorous science? A comprehensive 2026 narrative review published in Sports Medicine by Mendias and Awan takes a hard look at both approved and unapproved peptides currently circulating in the sports medicine space, offering clinicians and patients a much-needed framework for evaluating these compounds through an evidence-based lens.

What This Study Found

The review examined the pharmacological mechanisms, safety profiles, and regulatory status of a wide range of peptides marketed to patients — both those that have received regulatory approval and those operating in what the authors describe as a "gray market" outside of regulatory oversight. The peptides reviewed included BPC-157 (body protection compound 157), TB-500 (thymosin beta-4 fragment), CJC-1295, ipamorelin, sermorelin, tesamorelin (Egrifta), AOD-9604, FS-344 (follistatin-344), GHK-Cu, MOTS-C, SS-31 (elamipretide), and Tβ4 (thymosin beta-4).

Researchers found that peptides occupy a unique pharmacological position — they are short chains of amino acids that fall between small-molecule drugs and large protein biologics. This structural characteristic gives them distinct advantages in terms of tissue targeting and metabolic activity, which helps explain their appeal in sports medicine contexts.

However, the study draws a critical distinction between approved and unapproved compounds. Peptides such as tesamorelin (Egrifta) and sermorelin have undergone rigorous regulatory evaluation establishing both safety and efficacy for specific indications. Many of the unapproved peptides popularized in athletic and recovery communities — including BPC-157 and TB-500 — have demonstrated favorable tissue repair and metabolic outcomes in animal models, but the authors caution that rigorous human safety data remain scarce. The study explicitly states that there is potential for serious harm to patients using these compounds.

The review also raises an important and underappreciated issue: the role of the placebo effect. Researchers suggest that social media amplifies perceived efficacy by creating communities of belief around certain peptides, which may meaningfully inflate self-reported outcomes. This does not mean the compounds have no biological activity, but it underscores why anecdotal reports — however compelling — cannot substitute for controlled clinical evidence.

Clinical Significance

For sports medicine clinicians, this review provides an important reference point. The study suggests that patient demand for peptide therapies is outpacing the available evidence, creating a challenging clinical environment in which practitioners must balance patient autonomy with harm reduction and scientific integrity.

The authors provide a framework designed to help clinicians navigate patient conversations about peptides — an increasingly necessary tool as direct-to-consumer marketing of these compounds expands. This is particularly relevant because many patients arrive at clinical appointments already using unapproved peptides purchased online, often without any medical supervision.

From a mechanistic standpoint, the study highlights that several unapproved peptides act on growth hormone secretagogue pathways (such as CJC-1295 and ipamorelin), muscle regulatory pathways (such as FS-344, which targets follistatin), or mitochondrial and cytoprotective pathways (such as MOTS-C and SS-31). While these mechanisms are biologically plausible and show promise in preclinical settings, the researchers emphasize that animal model data cannot be directly extrapolated to human clinical outcomes without controlled trials to confirm safety and effectiveness in people.

The review also notes that alternative evidence-based treatments for musculoskeletal healing and athletic performance exist and should be considered as part of any comprehensive treatment plan. These include established rehabilitation protocols, nutritional strategies, and approved pharmacological options — all supported by a stronger human evidence base.

Current Access and Compliance Context

One of the more nuanced aspects of this review is its frank discussion of the regulatory landscape. Many of the peptides generating the most buzz in athletic communities are not approved by regulatory agencies such as the FDA for the indications in which they are being used. The authors describe a parallel gray market that has emerged largely outside of regulatory oversight, driven by patient demand and aggressive online marketing.

This has significant compliance implications. Several unapproved peptides are also prohibited under the World Anti-Doping Agency (WADA) code, meaning that competitive athletes who use them risk sanctions in addition to potential health consequences. Clinicians working with competitive athletes should be particularly attentive to the regulatory and anti-doping status of any peptide under discussion.

It is worth noting that the existence of a gray market does not mean all peptide use is equivalent in risk. Approved peptides such as tesamorelin have established dosing protocols, known side effect profiles, and pharmacovigilance systems in place. Unapproved compounds lack these safeguards, and the purity, concentration, and sterility of gray-market products cannot be guaranteed — a point the study underscores as a meaningful safety concern.

What Patients Should Know

If you are an active individual or athlete who has heard about peptide therapies and is curious about their potential, the findings of this review offer several important takeaways:

Animal data is not human data. Many of the unapproved peptides showing exciting results in laboratory and animal studies have not yet been tested in rigorous human clinical trials. The study suggests that while the mechanistic science is often compelling, it is premature to assume these findings will translate directly to safe and effective outcomes in people.

Social media is not a clinical trial. The researchers specifically highlight how online communities can amplify the placebo effect, making it difficult to separate genuine physiological benefit from expectation-driven improvement. Testimonials and influencer endorsements are not substitutes for peer-reviewed evidence.

Regulatory status matters for your safety. Purchasing and using unapproved peptides from unregulated sources carries real risks, including unknown purity, incorrect dosing, and the absence of long-term safety data. These are not theoretical concerns — they represent genuine patient safety issues identified in this review.

A qualified physician is your best resource. The study was developed in part to give clinicians better tools to have honest, informed conversations with patients about peptides. If you are considering any peptide therapy, speaking with a knowledgeable sports medicine physician who stays current on the evidence is the safest and most effective path forward.

Conclusion

The 2026 review by Mendias and Awan represents one of the most thorough and balanced assessments of peptide therapies in sports medicine published to date. It acknowledges the genuine scientific interest surrounding these compounds while being transparent about the significant gaps in human evidence — particularly for the unapproved peptides most aggressively marketed to athletes and active patients. As this field continues to evolve, working with a qualified, evidence-informed physician is essential to making safe and effective decisions about peptide therapies.

If you are looking for a clinician who understands the current state of peptide research and can help you navigate your options responsibly, visit peptideassociation.org/find-a-doctor to find a qualified provider near you.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice. The information presented here is based on published research and should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment or therapy, including peptide-based therapies.

---

Citation: Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026 Aug. doi:10.1007/s40279-026-02437-0. PMID: 41966639.